

Product Name	: Ladarixin sodium
Cat. No.	: PC-61475
CAS No.	: 865625-56-5
Molecular Formula	: C ₁₁ H ₁₁ F ₃ NNaO ₆ S ₂
Molecular Weight	: 397.315
Target	: Chemokine Receptor (CCR and CXCR)
Solubility	: 100 mM in DMSO



Biological Activity

Ladarixin sodium (DF-2156) is an allosteric, noncompetitive dual **CXCR1/2** inhibitor that inhibits human polymorphonuclear leukocyte (PMN) migration to CXCL8 in vitro with IC₅₀ of 0.7 nM.

Ladarixin prevents PMN infiltration and tissue damage in several models of IR injury in vivo.

Ladarixin abrogates motility and induces apoptosis in cultured cutaneous and uveal melanoma cells and xenografts.

Ladarixin also prevents inflammation-mediated damage in MLD-STZ, prevents and reverses diabetes in NOD mice.

References

Garau A, et al. *Eur Cytokine Netw.* 2006 Mar;17(1):35-41.

Citro A, et al. *Diabetes.* 2015 Apr;64(4):1329-40.

Kemp DM, et al. *Oncotarget.* 2017 Feb 28;8(9):14428-14442.

Bertini R, et al. *Br J Pharmacol.* 2012 Jan;165(2):436-54.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com
